• Forum
  • Aktiemarknader
    • BörsRealtidskurser, index och marknadsutveckling
    • MorgonrapportDaglig marknadssammanfattning och nattens viktigaste händelser
    • BörskalenderKommande resultat, noteringar och företagshändelser
    • UtdelningskalenderKommande och tidigare utdelningar
  • Bolag
    • BolagBläddra och filtrera hela listan över noterade bolag
    • UpptäckInspiration till din nästa investering
    • BörsnoteringarNya noteringar och kommande börsintroduktioner
    • ÅrsstämmorDatum för årsstämmor och aktieägarinformation
  • Aktieforskning
    • AktieanalysExpertaktieanalys och rekommendationer
    • ArtiklarNyheter, insikter och marknadskommentarer
    • PortföljInderes modellportfölj
    • inderesTVVideohub för aktieanalys, forskning och expertkommentarer
    • TranskriptionerFullständiga utskrifter av resultatsamtal och investerarmöten
    • AktiejämförelseJämför nyckeltal och utveckling för flera aktier
Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Q&A
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer

Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.

Regulatoriskt pressmeddelande

Gustav Sten appointed CEO of IDL Diagnostics

IDL Diagnostics
Ladda ner börsmeddelandet

IDL Diagnostics today announces that the Board of Directors has appointed Gustav Sten as the new Chief Executive Officer (CEO). Gustav Sten will assume the position on May 28, immediately following the Annual General Meeting, succeeding Anders Hultman.

Gustav Sten most recently served as Chief Marketing Officer (CMO) at IDL Diagnostics and has been with the company for eight years. He holds a Bachelor’s degree in Chemical Engineering and brings extensive experience in sales, development, production, and quality control of diagnostic products.

“We are very pleased to appoint Gustav Sten as our new CEO. During his years with the company, he has developed a deep understanding of our operations and has played a central role in driving our commercial development, most recently as Chief Marketing Officer. Gustav has also been a key contributor to our strategic initiatives, not least in developing our collaboration with concile. The Board is confident that he has the right expertise and drive to accelerate the company’s continued development, both within the rapid diagnostics segment and our focus on automated platforms,” says Max Pihlqvist, Chairman of the Board. 

Gustav Sten comments on his new role: 

“I am both excited and confident as I take on the role of CEO of IDL Diagnostics. Over the past five years, Anders has made a strong contribution in scaling the business and the organization. I now look forward to placing an even greater focus on commercialization and thereby driving further growth. We have a very exciting period ahead of us, both for our rapid tests and our products for automated platforms.” 

Contacts


Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@idldiagnostics.com

About IDL Diagnostics


IDL Diagnostics AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. IDL Diagnostics' product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. IDL Diagnostics (IDLDX) is listed on Nasdaq First North Growth Market with Redeye Sweden AB as company's Certified Adviser. For more information; www.idldiagnostics.com

This information is information that IDL Diagnostics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-05-19 09:00 CEST.

Attachments


Gustav Sten appointed CEO of IDL Diagnostics